Given as a prophylactic treatment, a single muscle electrogene transfer of plasmid coding canstatin fused to human serum albumin (CanHSA), slowed down the development of two xenografted human carcinomas from mammary (MDA-MB-231) and prostate origin (PC-3) in nude mice and delayed lung metastatic spreading of B16F10 melanoma cells in syngenic mice. No effect was observed with unfused canstatin. The long lasting circulating blood level of CanHSA (20 ng ml À1 ) resulted in a profound disorganization of the tumor blood vessel network. However, when used as a curative treatment, on well-established tumors, CanHSA electrogenetherapy was ineffective in reducing tumor growth.
Introduction
It is now well established that angiogenesis represents a critical process for invasive tumor growth and metastasis. [1] [2] [3] The switch involving conversion of quiescent endothelial cells to an active proangiogenic phenotype requires both upregulation of endogenous angiogenic stimulators and downregulation of endogenous angiogenesis inhibitors. 4 Targeting tumor angiogenesis to control tumor growth is a widespread approach and numerous preclinical and clinical studies have focused on the development of new angiogenesis inhibitors. [4] [5] [6] [7] [8] The extracellular matrix (ECM) surrounding blood vessels plays an essential role in both the angiogenic process and the vessel morphogenesis. Although, previously, several studies highlighted the antiangiogenic activity of angiostatin, 2 a non-ECM-derived plasminogen fragment, interestingly, most naturally occurring angiogenesis inhibitors are fragments or cryptic domains from ECM-derived larger proteins that are themselves not active as angiogenesis inhibitors. Endostatin, a collagen XVIII fragment, is the representative for endogenous inhibitors of angiogenesis derived from the ECM. 3 More recently, other cleavage products of ECM proteins were shown to also exert antiangiogenic properties, including tumstatin, 9 arresten, 10 canstatin [11] [12] [13] which are derived from collagen type IV.
A limitation to the therapeutic use of these angiogenic inhibitors is the large amount of purified recombinant proteins, in the milligram range, that should be administered daily in mice through experimental procedures. Thus, gene therapy appears as an appealing strategy to achieve the production and document the efficiency of antiangiogenic factors in preclinical studies. Extensive data have already shown that delivery of genes encoding angiogenesis inhibitors could effectively inhibit tumor growth in mice. A wide variety of carriers has been used to perform gene transfer. Adenovirus constructs with genes encoding angiostatin, 14, 15 endostatin 16 and canstatin 17 have been developed. Liposomes-DNA complexes encoding angiostatin and endostatin 18 were also found to be effective.
Gene electrotransfer of naked plasmid DNA (pDNA) is a recently developed technology, [19] [20] [21] [22] which is particularly attractive because of its simplicity, its lack of immune responsiveness and its safety. The pDNA electrotransfer in muscle mediates a substantial gene expression that lasts several months as demonstrated in mouse, 19, 21 with circulating transgene levels reaching 10-250 ng ml À1 , as reported for interleukin-10 (IL10) or IL12, 23, 24 for PDGF receptor-immunoglobulin G (IgG) 25 for interferon receptor-IgG1 26 and for angiostatin K1-5 fragment of plasminogen. 21 Previous work from our laboratory, 21 demonstrated that the circulating level of angiostatin delivered by muscle gene electrotransfer in mice is sufficient to induce some remote therapeutic effect. However, these plasma levels are generally much lower than those driven from a viral vector, 21 thus limiting applications only to prophylactic treatments. Research and development of molecules biologically active at low concentration will be precious for the future of the gene electrotransfer.
Powerful angiogenesis inhibitors, which are derived from collagen type IV, were described as being at least 10-fold more active than human endostatin. 9, 11 One of these inhibitors, the NC1 domain of collagen IV, named canstatin which was fused with human serum albumin (CanHSA) in order to increase its bioavailability, was found to exhibit a higher antitumor activity than HSAfused angiostatin K1-3. 17 As canstatin has been shown to be active in mice at low doses, 11 we have investigated the anticancer potential of CanHSA, endogenously produced in mice muscles following gene electrotransfer. In the present paper, several experimental protocols were designed and assessed for their relative effectiveness on diverse types of cancers in mice as prophylactic or curative therapies. Interestingly, we have shown here that CanHSA, delivered by gene electrotransfer, increases the curative potential of radiotherapy, thus providing promising preclinical data for establishment of therapeutic schemes in clinical practice.
Results

pBiCanHSA-electrotransferred muscles of mice produce doxycycline-regulated secretion of CanHSA in the bloodstream
Animals were submitted to a DNA electrotransfer protocol as specified in Materials and methods. Briefly, mice muscles were electrotransferred with doxycyclinregulated pBi or pBiCanHSA plasmid together with the regulatory plasmids. Sera were collected from each mouse a week after the gene electrotransfer and CanHSA levels were monitored by HSA enzyme-linked immunosorbent assay (ELISA) to determine whether muscle expression of CanHSA leads to its secretion in the bloodstream. As shown in Figure 1a , CanHSA serum levels were turned on only in animals that received pBiCanHSA, reaching a value of 20 ng ml À1 on average. Gene expression was undetectable in control animals. The difference between the two groups was statistically significant (Po0.001).
Three weeks after the DNA electrotransfer and continuous doxycycline stimulation, the animals were killed and the presence of CanHSA in muscle sections was visualized after immunochemical labeling with anti-HSA antibodies (Figure 1b) . Positive immunohistochemical brown staining was found only in myofibers from animals electrotransferred with pBiCanHSA. The coloration was particularly strong at the periphery of the fibers (Figure 1b ), suggesting a high-level secretory process.
Blood half-life of CanHSA produced from pBiCanHSA-electrotransferred muscles
The doxycycline-inducible promoter was exploited to determine the in vivo circulating CanHSA half-life in nude mice. Animals electrotransferred with pBiCanHSA received doxycycline in their drinking water for 1 week from the day of electrotransfer in order to establish a stable level of circulating CanHSA (level referred as 100% at time 0 of the kinetic). From then on, the animals were transferred into a new cage, doxycycline treatment was stopped and blood collection started at the indicated time points. CanHSA serum levels were measured by HSA ELISA. As a consequence of doxycycline withdrawal, CanHSA serum levels gradually declined to reach undetectable levels on day 14 ( Figure 2) . A mean half-life of 3.9 days was calculated from the graph.
Prophylactic control of tumor growth in mice electrotransferred with pBiCanHSA Seven days after either pBi or pBiCanHSA DNA electrotransfer, mice were inoculated subcutaneously with a suspension of MDA-MB-231 human adenocarcinoma mammary cells (4 Â 10 6 cells per animal). Serum levels of CanHSA were monitored twice during the experimental period, and tumor growth was monitored once a week for 4 weeks. CanHSA serum levels measured by ELISA reached a mean level of 12 ng ml À1 and were found to be stable all over the experimental period (data not shown). As shown in Figure 3a , a significant (P ¼ 0.01) tumor growth inhibition, 69%, was observed in pBiCanHSA-treated group as compared with control group. CanHSA gene electrotransfer and radiotherapy C Magnon et al Previous work showed that the antitumor effect of canstatin is partly due to the inhibition of intratumor vascularization. 17 Thus, to determine whether the circulating transgenes, produced after muscle pBiCanHSA electrotransfer, targeted the neovascularization, the experiment was repeated in similar conditions as described above, except that MDA-MB-231 tumors were removed 1 week after grafting to analyze the nascent vasculature. Blood vessel immunohistological staining was performed on tissue sections using an anti-CD34 antibody and the vessel density was quantified from the brown coloration by a fully automatized image processing, the PICXYT software. 27 As expected, a significant decrease (P ¼ 0.001) in intratumoral vessel density was observed in the CanHSA treated group when compared with the controls (Figure 4a) . Interestingly, the CanHSA therapy was found to affect vessel organization within the tumor mass as demonstrated by the significant decrease (P ¼ 0.007) of the hot spots (vessels clusters) as compared with the control (Figure 4b) .
The growth of an aggressive prostate tumor model, called PC-3, was then studied in nude mice electrotransferred with pBiCanHSA. The experimental protocol was the same as that described for the MDA-MB-231, except the number of grafted cells increased to 5 Â 10 Finally, the suppressive effect of an electrogenetherapy with pBiCanHSA on lung metastasis dissemination was evaluated on C57BL/6 mice intravenously injected with B16-F10 murine melanoma cells (1 Â 10 5 cells per animal) through the retro-orbital sinus. Two days following the tumor cell injection, the animals underwent DNA electrotransfer and transgene doxycyclin induction. Eight days later, the mice were killed, and lung metastatic foci counted under a dissecting microscope.
A significant (Po0.01) reduction, 65%, was observed in animals expressing CanHSA as compared with control animals ( Figure 3c ).
Similar experiments have also been performed using plasmid expressing unfused canstatin instead of CanH-SA for the three tumor types. In all cases, a slight decrease in tumor growth was observed, as previously described following an adenoviral infection. 17 However, the differences with the control groups were never significant (data not shown).
pBiCanHSA-muscle electrotransfer does not inhibit established tumor growth
Mice carrying prostatic PC-3 tumors, 65-112 mm 3 in volume, were randomized and submitted to a gene CanHSA gene electrotransfer and radiotherapy C Magnon et al electrotransfer into the muscle with pBiCanHSA. The results (data not shown) demonstrated that the treatment failed to inhibit tumor growth, indicating that the level of circulating CanHSA produced from the electrotransferred muscle (20 ng ml À1 mean values) is too low to provide a therapeutic benefit on established aggressive tumors.
Radiation and pBiCanHSA gene electrotransfer act synergistically to inhibit growth of established aggressive tumors Therapeutic strategies for cancer treatment have successfully associated radiations with antiangiogenic therapy. [28] [29] [30] [31] Recently we highlighted the mechanism of action explaining the therapeutic advantage combining adenoviral-delivered CanHSA with radiations. 32 We then addressed, here, the question of whether CanHSA gene electrotransfer could enhance radiations effects for the treatment of pre-established aggressive tumors.
Nude mice carrying prostatic PC-3 tumor, 120 mm 3 in average, were randomized and muscle electrotransferred with either pBi or pBiCanHSA plasmids. When tumor volume reached 400 mm 3 , each group was then divided into two parts with equal numbers of animals in each part. One part of the animals served as the control (not irradiated), and the other received 1.5 Gy radiation a day, for 5 consecutive days. Animals were killed 8 days post irradiation (Figure 5a ). At the end of the treatment, a significant reduction of PC-3 tumor growth, 46% (P ¼ 0.001) and 66% (Po0.001), respectively, were observed for animals submitted to radiations alone and bitherapy as compared with the control group (Figure 5b) . The differential efficacy of bitherapy over irradiation alone is statistically significant (P ¼ 0.01) and indicates an enhanced response to this treatment regimen.
Combining ionizing radiation and CanHSA reduces tumor vessel density and induces a massive apoptosis of PC-3 tumor cells
Having previously shown that CanHSA acts directly on both endothelial and tumor cells, 17, 32 to verify the specific mechanism underlying potentialization of the effects of CanHSA gene electrotransfer and radiations, microvessel density and tumor apoptosis were analyzed within tumors from nude mice submitted to either mono-or bitherapy.
PC-3 tumors were resected at the time of killing for immunohistological examination using anti-CD34 staining. Microvessel density was quantified on scanned plates using the PIXCYT automatized software. Data showed a significant decrease (Po0.02) in vessel density for bitherapy-treated tumors whereas no difference could be detected for tumors treated either with CanHSA or radiotherapy (slight but nonsignificant decrease; Table  1 ). These data suggest that substantial inhibition of tumor growth following bitherapy treatment was secondary to impaired tumor vasculature.
Terminal transferase dUTP nick-end labeling (TUNEL) analysis was performed in situ on tumor paraffin sections to quantify the proportion of apoptotic cells. As shown in Figure 6 , the number of apoptotic cells was significantly increased in tumors from animals submitted to bitherapy (21 cells per field; Po0.001) as compared to those treated with either radiotherapy (3 cells per field) or CanHSA (10 cells per field). Our results show that ionizing radiation and concomitant CanHSA produce greater than additive local antitumor effects (P ¼ 0.05), thus suggesting a synergistic antitumor interaction between the two modalities. This observation is consistent with our previous studies. 17, 32 To further confirm whether bitherapy-induced apoptosis was secondary to a strong hypoxia induction, we analyzed by immunohistochemistry and quantified by PIXCYT automatized software the expression of Glut-1 (glucose transporter), an HIF1 responsive gene (Figure 7) . On day 5 after the irradiation period, a twofold increase was observed in area fraction of Glut-1-stained tumor cells between radiotherapy alone and the combined therapy. Taken together, according to our previous study, 17, 32 these results showed that radiation alone induced HIF-1-dependent survival angiogenic pathways. Conversely, bitherapy triggered a significant upregulation of tumor hypoxia and apoptosis, decreasing angiogenic resistance to radiation.
Discussion
Electrotransfer is a recent and promising nonviral approach for gene therapy which displays numerous advantages such as easiness, safety, lack of both pathogenicity and immunogenicity. However, a major drawback of this technology is the relatively low transfection efficiency compared to viral vectors. A preclinical evaluation study was carried out to evaluate both antiangiogenic and antitumor activity of canstatin CanHSA gene electrotransfer and radiotherapy C Magnon et al fused with HSA when it is secreted from muscle tissue following gene electrotransfer. The present study also aimed at exploring whether radiotherapy treatment of experimental tumors grafted in nude mice could benefit from a combination with a low expression of this powerful antiangiogenic molecule.
In this study, the gene electrotransfer provides here a unique delivery system of three plasmids within the mouse muscle, where the transgene is under the control of a tetracyclin-inducible promoter as previously described. 21 CanHSA is produced within muscle fibers, as demonstrated by immunohistochemistry, and secreted into the bloodstream. A single injection of equimolar amounts of both coding and regulatory plasmids followed by eight square-wave electric pulses of 280 V cm À1 of 20 ms generates stable long-lasting levels of CanHSA (20 ng ml À1 in average) after doxycyclin induction. Previous electrogenetherapy studies showed that antiangiogenic agents, such as K1-3HSA, endostatinHSA and IL10, were secreted at 250, 200 and 10 ng ml À1 respectively. 21, 23 CanHSA seric level is thus in the range of values previously reported. More precisely, CanHSA (89 kDa) is cleared from the bloodstream of nude mice with a half-life of 3.9 days; this value is very similar to the half-life of 3.7 days previously reported for K1-3HSA (103 kDa), 23 which is consistent with the molecular weight of the proteins.
We first showed that CanHSA gene electrotransfer into the muscle following a prophylactic protocol significantly slows down the development of two human carcinomas from mammary, MDA-MB-231, and prostate, PC-3, origins, grafted in nude mice, as well as the lung metastatic spreading of B16F10 melanoma cells in Abbreviation: CanHSA, canstatin fused to human serum albumin. Four animals per group were treated as described in Figure 5 . PC-3 tumor histological sections were immunostained using an anti-CD34 antibody, tissue sections were scanned, non-necrotic area were selected on the scanned plates and brown staining quantified using a automatic PIXCYT software. Results are expressed as mean±s.e.m.
CanHSA gene electrotransfer and radiotherapy C Magnon et al syngenic mice. Nevertheless, in the three experimental models, expression of unfused canstatin never resulted in statistically significant tumor growth inhibition as compared to the control groups (data not shown). As expected, the antitumor efficacies of unfused and fused canstatin are related to their respective bioavailability. The increase in molecular weight, from 24 kDa for canstatin to 89 kDa for canstatin fused with HSA, likely contributed to a reduced renal clearance. 33 CanHSA is found to induce a statistically significant and strong inhibition of tumor growth (around 60-69%, according to the tumor types) and this, in spite of a low level of circulating CanHSA (20 ng ml
À1
). Increasing the amount of plasmid used in the electrotransfer process does not result in an interesting gain in term of transgene circulating level (D Renoir, unpublished results). Interestingly, the plasma level of CanHSA driven by gene electrotransfer, which is 25-fold lower than the one driven by a recombinant adenovirus, 17 appears sufficient to prevent tumor growth, thus giving to CanHSA a valuable therapeutic index when delivered by gene electrotransfer. The secretion of CanHSA into the bloodstream rapidly disorganizes the blood vessel network, as shown by a significant decrease of CD34 immunostaining in the MDA-MB-231 tumor models. We have previously established 17 that CanHSA sensitivity can be predicted based on integrin gene expression profiles. Indeed, the CanHSA-triggered apoptotic process is induced by the binding of CanHSA to avb3 and avb5 integrins which mediate endothelial and tumor cells adhesion and migration to the ECM. 34, 35 On the other hand, following curative protocol, tumor growth is not significantly inhibited when CanHSA is gene electrotransferred into muscles of animals carrying large pre-established tumors that already developed a mature vessel network. At least two explanations, not mutually exclusive, can be advanced to account for this observation-either a mature tumor blood vessel network might be unable to respond to a change in balance between proangiogenic and antiangiogenic factors or-the level of circulating CanHSA would be below the threshold required to counteract the activity of proangiogenic factors highly produced by the growing tumor. Tumor regression which follows the intratumoral injection of a recombinant adenovirus producing a locally elevated concentration of CanHSA supports this latter hypothesis. 17, 32 Antiangiogenic gene electrotransfer protocols previously described in preclinical studies only acts as prophylactic treatments. 21 This is a major drawback for a clinical use of this factor. In this context, combinational therapies appear to be needed. Combinations with prevalent treatments such as radiotherapy or chemotherapy have been proposed for other antiangiogenic factors. Angiogenic inhibitors are known to improve the therapeutic index of radiotherapy. [28] [29] [30] [36] [37] [38] [39] [40] [41] Recently, we have demonstrated the benefit of combining radioiodide therapy with angiogenic inhibitors, such as CanHSA. 32 The benefit of this association is extended in the present study to a virus free bitherapy combining CanHSA gene electrotransfer with fractionated external beam radiotherapy on large PC-3 pre-established tumors in nude mice. Interestingly, our data show an enhancement of the radiation-generated tumoricide effects in animals expressing CanHSA in their circulation due to a dual targeting of both endothelial and tumor cells. Figure 7 PC-3 tumors hypoxia in response to a curative treatment combining canstatin fused to human serum albumin (CanHSA) gene electrotransfer and irradiation in nude mice. Animals were treated as described in Figure 5 . The tumors were removed on the day of animal killing, fixed and embedded in paraffin. Sections were stained anti-glut1 antibody, quantification of staining was made after scanning using an automatized PIXCYT software. Results are expressed as mean±s.e.m. (n ¼ 4 animals in each group).
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Radiations are known to induce tumor cell apoptosis through increased p53 phosphorylation. As expected, PC-3 cells which are p53-null 42 are found to be radioresistant ( Figure 6 ) and their radiosensitization by CanHSA is not likely linked to p53 pathway. The present work clearly shows that the combination of radiations with CanHSA gene electrotransfer increases the tumor apoptotic process in animals, highlighting our recent findings. 32 Such bitherapy first contributes to strongly enhance endothelial cell death, which induces tumor hypoxia, a step essential to further trigger CanHSAmediated direct tumor cell apoptosis. As demonstrated recently, 32 CanHSA induces the apoptotic process through binding to a v b 3 and a v b 5 integrins, which are specific receptors for canstatin. However, in endothelial cells, these receptors are endogenously expressed, whereas in tumor cells they are HIF-1a expression dependent. 17, 32, 43, 44 Consequently, the CanHSA-triggered endothelial cell death is not dependent on HIF-1a expression, conversely, to mediate tumor cell apoptosis, CanHSA requires HIF-1a stabilization to increase tumor expression of a v b 3 and a v b 5 integrin receptors and to mediate tumor cell apoptosis. Tumor cell death is thus a secondary event that depends on endothelial cell death, provoked by the combination of radiations with CanHSA, in order to increase HIF-1a expression. 32, [45] [46] [47] [48] Thus interestingly, the HIF-1-dependent radioresistance, which usually follows radiation alone, is therefore overridden by the HIF-1-dependent apoptotic process induced by canstatin. 32, 45, 46 About 60% of all cancer patients receive radiotherapy during the course of their disease making this treatment modality an important standard cancer treatment. Dose escalation and combination with chemotherapy have largely contributed to expand the therapeutic index of radiation therapy. Combined antiangiogenic electrogenetherapy with external beam radiotherapy appears a promising virus-free curative protocol opening the door to many potential applications in cancer therapy. As example, treatment of prostate cancer that often develops radioresistance could benefit from this extremely simple radio-genetherapy protocol.
Materials and methods
Plasmid DNAs
The pBi, pTet-On and pTet-tTS plasmids were obtained from Clontech (Palo Alto, CA, USA). The HpaI-NheI restriction fragments from pCMCan or pCMCanHSA, expressing the C-terminal NC1 domain of the human a2 chain of type IV collagen, also called canstatin (24 kDa) (GenBank accession GI 81011723), either fused (CanHSA) or unfused (Can) to a HSA moiety, were cloned between the EcoRV and NheI sites of the pBi vector (Clontech) to generate pBiCan and pBiCanHSA. Both Can and CanHSA are secreted by virtue of the 24-residue prepro signal sequence from HSA (GenBank accession E01107), which was inserted into the N-terminal of both proteins. pDNAs were prepared using a Qiagen Endo-Free Plasmid Maxi Kit (Qiagen, Courtaboeuf, France). Purified pDNAs were solubilized in endotoxin-free 0.9% NaCl at the working concentration. 
Plasmid electrotransfer into skeletal muscle
Female Swiss nude mice, 8-9 weeks of age (Charles River, l'Arbresle, France), were housed in groups of five in barrier cages. Female C57BL/6 were purchased from Harlan (Gannat, France). All the animals were maintained with food and water ad libitum, with a 12-h light/ dark cycle. The animals were anesthetized for short periods in isoflurane (Belamont, Neuilly, France) prior to all procedures. Before the pDNA electrotransfer procedure, the animals were anesthetized via an intraperitoneal injection of the anesthetics: ketamine (100 mg kg The experimental conditions for electrotransfer have been described. 21 Briefly, 50 or 12 mg of either pBiCanHSA or pBiCan, 10 mg of pTet-tTS and 20 mg of pTet-On plasmids (equimolar amounts) were mixed, suspended in a total volume of 30 ml sterile 0.9% normal saline and then injected into the tibialis cranialis muscle of mice using a Hamilton syringe. Eight transcutaneous squarewave electric pulses of 280 V cm À1 and of 20 ms were applied by two stainless steel plate electrodes, approximately 5.7 mm apart, placed at each side of the leg, at a repetition frequency of 1 Hz using a PS-15 electropulsator (Jouan, St Herblain, France). The second leg was injected with the same amount of DNA and electrotransferred under the same conditions. The electrotransfer of a mixture of plasmid pBi and regulatory plasmids served as a control. Animals were continuously given water with doxycycline (200 mg ml
À1
) from the day of gene electrotransfer and then on to induced the transgene expression.
Protocol for in vivo irradiation
Mice received X-ray irradiation delivered at a dose of 1.5 Gy each day for 5 consecutive days, using a 250 kV RT Philips radiation source operating at 200 kV with a 0.2 mm Cu-filter.
Tumor cell inoculation in vivo
Cultured human MDA-MB-231 or PC-3 cells were harvested at 80% saturation using EDTA 0.2 g l À1 (Life Technologies), washed and suspended in sterile phosphate-buffered saline (PBS) and kept on ice. The final concentration was adjusted to 2 Â 0 7 cells per ml, and 200 ml (4 Â 10 6 cells) were injected subcutaneously into the back of nude mice. When specified, animals were Cultured B16-F10 melanoma cells were harvested at 80% saturation with EDTA 0.2 g l À1 (Life Technologies), washed with PBS and then suspended in sterile 0.9% normal saline, and kept on ice for a period not exceeding 30 min. The final concentration was adjusted to 2 Â 10 6 cells per ml. Lung metastases were established in syngeneic C57BL/6 mice by the intravenous injection of 2 Â 10 5 cells in a volume of 100 ml, via the retro-orbital sinus. Ten days after tumor cell injection, animals were killed by a lethal dose of CO 2 , the lungs excised and the metastases counted under a dissecting microscope.
HSA ELISA quantification
Western analysis showed that fusion protein CanHSA remain stable in vivo. 17 It is thus possible to follow the molecule via its HSA entity. Plates of 96-wells (NuncImmuno Plate; Brand Products, Denmark) were coated with 100 ml of rabbit anti-HSA antibody (A0433; SigmaAldrich), diluted to 1 mg ml À1 in PBS, and incubated at 4 1C overnight. The wells were then washed six times with TBST buffer (0.2% Tween 20 in 10 mM Tris, pH 7.4, buffered saline) and blocked for 3 h at room temperature with 200 ml per well of 5% nonfat milk (Regilait, Nestle, France) in TBST (TBST milk). After six washes, 50 ml per well of serum diluted 1/2 was added and incubated for 2 h at room temperature. Wells were then washed six times and 50 ml per well of goat anti-HSA antibody (A7544; Sigma-Aldrich) diluted to 1500 ng ml À1 was added. Following 2 h incubation at room temperature and six washes, 50 ml of alkaline phosphatase-conjugated rabbit antibody (1/5000 diluted in TBST milk) directed against goat IgG (H+L) was added (Jackson Immunoresearch, Baltimore, MD, USA). After 2 h incubation at room temperature and six washes, color was developed for 20 min using a Bio-Rad kit (Bio-Rad Laboratories, Hercules, CA, USA), and the absorbance was determined in a microplate reader (Dynex Technologies, Chantilly, VA, USA).
A calibration curve with purified HSA (SigmaAldrich) was run on each plate.
Immunohistological analysis. Paraffin sections (5 mm thick) were prepared. After xylene treatment and rehydration, hematoxylin/eosin/safranin-stained slides were prepared. Immunohistochemistry was performed as previously described. 21 Briefly for Glut-1, slides were incubated with an anti-glut-1 polyclonal rabbit antibody Neomarkers (Interchim, Montlucon, France), followed by a rabbit PowerVision-HRP incubation. For immunohistochemistry of CD34, slides were incubated with a rat anti-CD34 monoclonal antibody Mec 14.7 (Hycult biotechnologies, Uden, The Netherlands), followed by a rabbit anti-rat secondary antibody (Dako, Glostrup, Denmark) and a third step consisting in PowerVision rabbit-HRP incubation. The slides were revealed with DAB chromogenic substrate (PowerVision Immunovision Technologies, Microm, Germany), counterstained with Mayer's hematoxylin, and mounted in permanent medium (Pertex, Gö teborg, Sweden). All slides were immunostained in cover plates the same day, guaranteeing a perfectly standardized intensity of staining, both for the immunohistochemical signal and for the counterstaining.
Quantification of CD34-stained microvessels, or glut-1 expressing cells on histological slides was achieved using PIXCYT, a software package designed by the Groupe Régional d'Etudes sur le Cancer (Centre François Baclesse, Caen, France). 27 This system combines a dedicated slide scanner and a computer-assisted image analysis. Only the viable part of the tumors was analyzed, the necrotic area was excluded from the examinations.
Apoptotic cells quantification (TUNEL)
An in situ cell death detection kit employing the TUNEL method (Roche Applied Science, Basel, Switzerland) was used to detect apoptotic cells within paraffin sections. Five fields per animal were digitized at a magnification of Â 200. The number of stained cells per field was counted, the scoring was done in a double-blinded fashion and the mean values with their s.d. were then calculated.
Statistical analysis
Error terms are expressed as s.d. of the mean. Difference between groups were analyzed by the Student's t-test (unilateral and unpaired test), the difference was considered significant when P-value was p0.05.
